231 related articles for article (PubMed ID: 38651144)
1. Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer.
Fey SK; Vaquero-Siguero N; Jackstadt R
Cell Rep; 2024 May; 43(6):114270. PubMed ID: 38787726
[TBL] [Abstract][Full Text] [Related]
2. Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets.
Scarini JF; Gonçalves MWA; de Lima-Souza RA; Lavareze L; de Carvalho Kimura T; Yang CC; Altemani A; Mariano FV; Soares HP; Fillmore GC; Egal ESA
Front Oncol; 2024; 14():1275330. PubMed ID: 38651144
[TBL] [Abstract][Full Text] [Related]
3. The role of Eph receptors and ephrin ligands in colorectal cancer.
Herath NI; Boyd AW
Int J Cancer; 2010 May; 126(9):2003-11. PubMed ID: 20039322
[TBL] [Abstract][Full Text] [Related]
4. The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y; Du Z; Mou J; Qiu X; Chen J; Cai S; Ren D; Xiao F; Zhou G; Yuan C
Curr Med Chem; 2023; 30(20):2340-2353. PubMed ID: 35996244
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC
Corrado M; Giorgio C; Barocelli E; Marzetti GV; Cantoni AM; Di Lecce R; Incerti M; Castelli R; Lodola A; Tognolini M
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32316101
[TBL] [Abstract][Full Text] [Related]
6. Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity.
Darling TK; Lamb TJ
Front Immunol; 2019; 10():1473. PubMed ID: 31333644
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications.
Papadakos SP; Stergiou IE; Gkolemi N; Arvanitakis K; Theocharis S
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444544
[TBL] [Abstract][Full Text] [Related]
8. Eph receptors and ephrins in cancer progression.
Pasquale EB
Nat Rev Cancer; 2024 Jan; 24(1):5-27. PubMed ID: 37996538
[TBL] [Abstract][Full Text] [Related]
9. Optimization of the Lead Compound NVP-BHG712 as a Colorectal Cancer Inhibitor.
Tröster A; DiPrima M; Jores N; Kudlinzki D; Sreeramulu S; Gande SL; Linhard V; Ludig D; Schug A; Saxena K; Reinecke M; Heinzlmeir S; Leisegang MS; Wollenhaupt J; Lennartz F; Weiss MS; Kuster B; Tosato G; Schwalbe H
Chemistry; 2023 Apr; 29(23):e202203967. PubMed ID: 36799129
[TBL] [Abstract][Full Text] [Related]
10. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
11. Signals transduced by Eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers.
Lau A; Le N; Nguyen C; Kandpal RP
Cell Signal; 2023 Apr; 104():110579. PubMed ID: 36572189
[TBL] [Abstract][Full Text] [Related]
12. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
Torlot L; Jarzab A; Albert J; Pók-Udvari Á; Stahler A; Holch JW; Gerlinger M; Heinemann V; Klauschen F; Kirchner T; Kumbrink J; Küster B; Jung A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):669-682. PubMed ID: 36401637
[TBL] [Abstract][Full Text] [Related]
13. Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake.
Xu C; Gu L; Kuerbanjiang M; Jiang C; Hu L; Liu Y; Xue H; Li J; Zhang Z; Xu Q
Oncogene; 2023 Jan; 42(2):99-112. PubMed ID: 36376513
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
